GCP
FDMT icon

GSA Capital Partners’s 4D Molecular Therapeutics FDMT Stock Holding History

GSA Capital Partners’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-117,719
Closed -$437K – 1789
2025
Q2 		$437K Buy
+117,719
New +$414K 0.03% 1014
2025
Q1 		– Sell
-16,743
Closed -$93K – 1783
2024
Q4 		$93K Sell
16,743
-20,919
-56% -$164K 0.01% 1515
2024
Q3 		$407K Sell
37,662
-27,220
-42% -$452K 0.03% 1047
2024
Q2 		$1.36M Buy
+64,882
New +$1.63M 0.1% 315
2022
Q4 		– Sell
-23,997
Closed -$193K – 1594
2022
Q3 		$193K Buy
+23,997
New +$217K 0.03% 1236

Other funds holding FDMT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

GSA Capital Partners's FDMT Position: Q3 2025 in Review

GSA Capital Partners sold out of 4D Molecular Therapeutics (FDMT) in Q3 2025, closing a stake of 117,719 shares — an estimated $437K sold.

GSA Capital Partners first reported a position in FDMT in Q3 2022 and held it in 5 quarters. The position peaked at $1.36M in Q2 2024. 134 funds tracked by Wall St. Rank hold FDMT as of Q3 2025.

  • GSA Capital Partners reported no remaining 4D Molecular Therapeutics position as of Q3 2025 after selling out during the quarter.
  • GSA Capital Partners sold 117,719 4D Molecular Therapeutics shares in Q3 2025, an estimated $437K.
  • GSA Capital Partners first reported a position in 4D Molecular Therapeutics in Q3 2022 and held it in 5 quarters.
  • GSA Capital Partners's 4D Molecular Therapeutics position peaked at $1.36M in Q2 2024.
  • 134 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2025.

Based on GSA Capital Partners's 13F filing for Q3 2025, filed 7 Nov 2025.